Subtype
Head and Neck Carcinoma
CI-CAN-00000950Explore in graph →
1,013 active trials15 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000950Explore in graph →
Clinical trials
2,921 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (347)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06177301 | Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC | recruiting | Phase 3 | 266 | Fudan UniversityOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT06492460 | 2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma | recruiting | Phase 3 | 422 | Sun Yat-sen UniversityOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT06228079 |
| Adjuvant vs Surgery Only in Early-stage Recurrent NPC |
| recruiting |
| Phase 3 |
| 176 |
| Eye & ENT Hospital of Fudan UniversityOTHER |
| 1 |
| Jul 4, 2025 |
| clinicaltrials |
| NCT06235203 | Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC | recruiting | Phase 3 | 154 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT07000643 | Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma | recruiting | Phase 3 | 386 | Man HuOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06749899 | QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. | recruiting | Phase 3 | 580 | Sun Yat-Sen University Cancer CenterOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT06912698 | Reduced Dose Radiotherapy vs Standard Dose Radiotherapy for Early Stage Nasopharyngeal Carcinoma | recruiting | Phase 3 | 342 | Hai-Qiang Mai,MD,PhDOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06752239 | Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC(PROTECT-NPC) | recruiting | Phase 3 | 474 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06095154 | CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma | recruiting | Phase 3 | 474 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 13, 2025 | clinicaltrials |
| NCT06791005 | A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer. | recruiting | Phase 3 | 400 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT06669611 | Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma | recruiting | Phase 3 | 242 | Sun Yat-sen UniversityOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06601335 | A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | recruiting | Phase 3 | 510 | AkesoINDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06675214 | Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy. | recruiting | Phase 3 | 586 | Sun Yat-sen UniversityOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06248996 | a Multicentre Phase III Study of Risk-based Treatment Intensification With Hyperfractionated Radiotherapy in Head and Neck Cancer Patients(ARTSCAN VI) | recruiting | Phase 3 | 308 | Lund University HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06516133 | Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma(OART) | recruiting | Phase 3 | 494 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06383780 | Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis. | recruiting | Phase 3 | 90 | XIANG YANQUNOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06438627 | Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial | recruiting | Phase 3 | 164 | XIANG YANQUNOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT05582265 | Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I) | recruiting | Phase 3 | 537 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT05798793 | Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma(NEOPCOSCC) | recruiting | Phase 3 | 309 | Hospital of Stomatology, Wuhan UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06241599 | A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) | recruiting | Phase 2 / Phase 3 | 300 | Sun Yat-sen UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT06092957 | Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy | recruiting | Phase 3 | 504 | Sun Yat-sen UniversityOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT05125055 | Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC | recruiting | Phase 2 / Phase 3 | 80 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06102395 | Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC | recruiting | Phase 3 | 272 | Beijing Tongren HospitalOTHER | 1 | Oct 30, 2023 | clinicaltrials |
| NCT06026878 | GNT Induction Treatment in Locally Advanced NPC | recruiting | Phase 3 | 228 | Air Force Military Medical University, ChinaOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT05980715 | PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy(HNC-SYSU-003) | recruiting | Phase 3 | 324 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT03919552 | Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 3 | 482 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05877872 | Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma | recruiting | Phase 3 | 424 | Sun Yat-sen UniversityOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT05860868 | Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 3 | 474 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | May 16, 2023 | clinicaltrials |
| NCT05854849 | Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC | recruiting | Phase 3 | 244 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT05527470 | Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 3 | 440 | Wei JiangOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05772208 | Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy | recruiting | Phase 3 | 459 | Fudan UniversityOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05674305 | Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy | recruiting | Phase 3 | 366 | Fudan UniversityOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT04437329 | Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma | recruiting | Phase 3 | 352 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT05342792 | Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma | recruiting | Phase 3 | 556 | Sun Yat-sen UniversityOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT05044117 | Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) | recruiting | Phase 3 | 220 | Sun Yat-sen UniversityOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT05062005 | ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 3 | 447 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Sep 30, 2021 | clinicaltrials |
| NCT04376866 | Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma | recruiting | Phase 3 | 204 | Cancer Hospital of Guangxi Medical UniversityOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT04778956 | Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma | recruiting | Phase 3 | 218 | Sun Yat-sen UniversityOTHER | 1 | Mar 4, 2021 | clinicaltrials |
| NCT04448522 | Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma | recruiting | Phase 3 | 508 | Sun Yat-sen UniversityOTHER | 2 | Sep 28, 2020 | clinicaltrials |
| NCT04453813 | Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma | recruiting | Phase 3 | 226 | Sun Yat-sen UniversityOTHER | 1 | Sep 28, 2020 | clinicaltrials |
| NCT04136886 | Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma(IMRT) | recruiting | Phase 3 | 346 | Sun Yat-sen UniversityOTHER | 1 | Oct 23, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Aug 14, 2025source: clinicaltrials